{
    "root": "3b38a6a4-1d7f-4331-b416-f10ce6c32824",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Metformin Hydrochloride"
    },
    "value": "20250515",
    "ingredients": [
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "PEG-8",
            "code": "B697894SGQ"
        },
        {
            "name": "PEG-135",
            "code": "30IQX730WE"
        }
    ],
    "indications": "Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.",
    "contraindications": "Adult Dosage for Metformin Hydrochloride Tablets: Starting dose: 500 mg orally twice a day or 850 mg once a day, with meals (2.1) Increase the dose in increments of 500 mg weekly or 850 mg every 2 weeks, up to a maximum dose of 2550 mg per day, given in divided doses (2.1) Doses above 2000 mg may be better tolerated given 3 times a day with meals (2.1) Pediatric Dosage for Metformin Hydrochloride Tablets: Starting dose: 500 mg orally twice a day, with meals (2.2) Increase dosage in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses twice daily (2.2) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (2.3) Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 (2.3) Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 (2.3) Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m 2 (2.3) Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 (2.3) Discontinuation for Iodinated Contrast Imaging Procedures: Metformin hydrochloride tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures (2.4)",
    "warningsAndPrecautions": "Product:    50090-2081\n                  NDC:    50090-2081-0   60 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-2081-3   100 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-2081-4   30 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-2081-5   180 TABLET, FILM COATED in a BOTTLE, PLASTIC \n                  NDC:    50090-2081-6   90 TABLET, FILM COATED in a BOTTLE\n                  Product:    50090-2173\n                  Product:    50090-2177\n                  NDC:    50090-2177-0   60 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-2177-2   100 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-2177-4   90 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-2177-5   180 TABLET, FILM COATED in a BOTTLE, PLASTIC \n                  NDC:    50090-2177-3   30 TABLET, FILM COATED in a BOTTLE",
    "adverseReactions": "Metformin hydrochloride tablets are contraindicated in patients with: \n                  \n                  \n                     Severe renal impairment (eGFR below 30 mL/min/1.73 m2) [see Warnings and Precautions (5.1)].\n                     \n                     Hypersensitivity to metformin. \n                     Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma."
}